Screener
Jade Biosciences JBIO CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Jade Biosciences’s 10-K, filed March 6, 2026.
- Filed
- Mar 6, 2026, 4:15 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-096550
| Line item | Year Ended December 31, 2025 | Period from June 18,2024 (Inception) to December 31, 2024 |
|---|---|---|
| Purchases of investments | (261,194) | — |
| Proceeds from sales/maturities of investments | 14,415 | — |
| Payment of security deposit | (31) | — |
| Purchases of property and equipment | (196) | — |
| Net cash used in investing activities | (247,006) | — |
| Cash flows from financing activities: | ||
| Proceeds from issuance of convertible notes payable(1) | — | 95,000 |
| Payment of deferred offering costs | — | (3,000) |
Item 16. Form 10-K Summary
FAQ
- What is Jade Biosciences's capex?
- Jade Biosciences (JBIO) reported capex of $3K in Q4 2025.
- What is the long-term trend for Jade Biosciences's capex?
- Over 3 years (2021 to 2025), Jade Biosciences's capex has grown at a 2.7% compound annual growth rate (CAGR), from $181K to $196K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Jade Biosciences's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude